CClinicalTrials.gg
Status unknownNCT00534170YakultUpdated Sep 24, 2007

Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea

A Phase 3 interventional study of Probiotic (Yakult) in Diarrhea, sponsored by Indian Council of Medical Research. Status unknown at 1 site in India. Open to participants aged 12 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-09-24.

Sponsored by Indian Council of Medical Research · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2007), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
12 Months to 59 Months
Sex
All
01

Study summary

A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.

In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.

OBJECTIVES

Primary objectives:

  1. To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
  2. To assess the impact of probiotics on nutrition and growth of the children

Secondary Objectives:

  1. Reduction in duration, frequency of diarrhoea
  2. Identification of pathogens causing diarrhoea
  3. Examination of faecal microflora

STUDY DESIGN

It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.

Read the detailed description

A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.

In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.

OBJECTIVES

Primary objectives:

  1. To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
  2. To assess the impact of probiotics on nutrition and growth of the children

Secondary Objectives:

  1. Reduction in duration, frequency of diarrhoea
  2. Identification of pathogens causing diarrhoea
  3. Examination of faecal microflora

STUDY DESIGN

It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.

METHODOLOGY

Slum areas in Kolkata Municipal Corporation with approximately 60,000 populations (approximate 15,000 families) will be selected from ward 66 to reach a sample size of minimum 4,000 children (1-5 year age).

Baseline anthropometric measurements will be taken. The diarrhoeal surveillance will be through regular household visit by CHW and stool container will be kept at each child's house to collect stool sample if diarrhoea occurs.

INCLUSION/ EXCLUSION CRITERION FOR RECRUITMENT OF PARTICIPANTS Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form (Appendix 7) will be required from either of the parents/ guardians of each participating child. Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness.

Children with history of diarrhoea in the preceding 2 weeks will not be eligible.

ADMINISTRATION OF STUDY AGENTS

There will be a setup of 5 health outposts and 20 clusters (each cluster with 40 children) will be approximately of 800 children will be assigned for each health outpost. There will be 20 Community Health Workers (CHW), allocated in each health outpost will be responsible for administer of one agent code for 40 children.

SAFETY EVALUATION

Clinical monitor will evaluate adverse events due to intake of the drink.

DATA MANAGEMENT PROCEDURES

Data obtained from demographic survey (Appendix 4), daily reports and other proforma will be entered in a PC using suitable software. Data will be scrutinized for accuracy and consistency before it is entered into the PC. Data will be entered into computers in a dedicated area located at NICED, using data entry programs specially created for the project by programmer.

STATISTICAL CONSIDERATIONS

Endpoints

Efficacy will be assessed by comparing the following between the probiotic and nutrient groups:

i) Average duration of diarrhoea ii) Severity of the disease iii) Incidence of diarrhoeal disease iv) Nutritional gain v) Analysis of fecal microflora

ETHICAL ASSURANCE FOR PROTECTION OF HUMAN RIGHTS

Written informed consent will be obtained from the parent/guardian of each participating child for the Probiotic and Nutrition studies and for the safety and for permission to collect feces. The probiotic or nutritional drink is safe and has been administered to infant children, adults and the elderly.

Storage conditions

The probiotic and nutrient will be stored at 4 to 10C. Bottles taken to the field will be carried in carrying bags. Each box will have a single ice pack, and care will be taken not to freeze the contents of the bottle.

MONITORING, AUDITING, INSPECTION

Responsibilities of the investigator(s)

The principal and co-investigators at NICED will be responsible for overall supervision and management of the project. Field investigators and other co-investigators will support the PI. The PI and co-investigators will supervise all activities at health facilities and in the sites (demographic surveillance, data collection, and samples collection and transportation). They will also visit the study sites regularly.

ETHICAL AND REGULATORY STANDARDS

Ethical principle

The justification for using a nutrient in this study is that: 1) no probiotic is currently recommended for use for prevention of diarrhoeal diseases in public health programs in India and 2) a valid assessment of probiotic efficacy in Kolkata, which is endemic for diarrhoea, can only be obtained with use of a nutrient. The nutrient will consist of nutrient without lactobacillus, which will help for nutritional growth of the children.

Potential benefits

During both phases of the project, the potential benefits to participants include proper treatment and referral when needed, as well as free and accurate diagnosis of the causative agent of diarrhoeal disease. During the trial phase, the probiotic recipients are expected to benefit from the protection offered by the probiotic against diarrhoea.

Potential risks

The potential risk to the participants will be minimal, since there is extensive documentation for the safety of the probiotic to be used.

Risk/benefit ratio

The direct benefit the participants may expect from participating in this study will be free laboratory examination and treatment for diarrhoea diseases.

The main benefit of obtaining data on the efficacy of the probiotic in Kolkata will be that these data will be crucial in guiding the decision of the Indian, and perhaps other developing country governments as to whether this probiotic will be alternative approach for growth of the children as well as prevention of diarrhoeal diseases. All recipients of the probiotic will potentially benefit from the probable protective effects against diarrhoea. The risks associated with the use of the probiotic or the nutrient and various other study procedures proposed to be used in this trial are expected to be minimal to nonexistent.

Laws and regulations

The study will be performed in accordance with the principles that govern biomedical research involving human subjects, specifically the ICMR Ethical Guidelines, the Declaration of Helsinki, and the International Conference on Harmonization's Good Clinical Practice Guidelines to provide assurance that the rights, integrity, and confidentiality of trial subjects are protected and that reported results are credible and accurate.

Informed consent

Individual informed consents from parents of eligible children between 1-5 years old will be obtained. Consent will be documented by signature or thumbprint of the parents/guardian on separate sheet. The privacy and confidentiality of all data and information collected from trial participants will be ensured both during and after the conduct of the trial. Individuals will not be identified in any reports and publications based on the trial data.

Institutional review committee

Before initiation of the study, the final protocol and the informed consent will require clearance Scientific Advisory Committee of NICED, Institutional Ethics Committee of NICED, Health Ministry Screening Committee of the Government of India.

ADMINISTRATIVE ASPECTS

Record retention

The principal investigator and NICED will keep all trial documents for at least 5 years after the completion or discontinuation of the study.

KEY PERSONNEL Name Professional Discipline/ Specialty Role in the Project

    1. Dipika Sur Epidemiology PI in India
    1. S.K. Bhattacharya Cholera and enteric disease Co-PI in India
    1. Byomkesh Manna Epidemiology Co-I in India
    1. S.K. Niyogi Microbiology Co-I in India
  1. 6 Anup Palit Microbiology Co-I in India
    1. S.P. Mukhopadhyay Public health Controller
    1. Ashok Chowdhury Clinician Clinical Monitor
02

Conditions studied

  • Diarrhea

Browse trials for

Keywords

  • Probiotic
  • Prevention of diarrhoea
  • Nutritional status
03

In context

Diarrhea

852 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

This study's enrollment of 4,000 is above the median of 136 across 713 interventional studies indexed under Diarrhea.

Browse Diarrhea studies →

Lead sponsor

Indian Council of Medical Research is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form will be required from either of the parents/ guardians of each participating child.
  • Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness

Exclusion criteria

Exclusion Criteria:

  • Children below -2SD of the National Center for Health Statistics (NCHS) reference median in the nutritional parameters will not be enrolled.
  • Children with history of diarrhoea in the preceding 2 weeks will not be eligible.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,000 participants (actual)

Study arms

  • Experimental
    A,F,T,K

    Two arms are for intervention and two are for control or placebo

    Dietary Supplement: Probiotic (Yakult)

Interventions

  • Dietary supplementProbiotic (Yakult)

    It is a dietary supplement ,65 ml containing 15 billion lactobacillus

    Also known as: Yakult

06

What researchers measure

Primary outcomes

  1. Diarrhoeal episodes in children

    Time frame: 10 months

Secondary outcomes

  1. nutritional status in children

    Time frame: 10 months

07

Study locations

1 site
  • National Institute of Cholera and Enteric Disease
    Kolkata, West Bengal 7000010, India
08

References and documents

Publications

  • Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A, Nomoto K, Takahashi T, Shima T, Tsuji H, Kurakawa T, Takeda Y, Nair GB, Bhattacharya SK. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect. 2011 Jun;139(6):919-26. doi: 10.1017/S0950268810001780. Epub 2010 Jul 30. PubMed 20670468 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00534170
Lead sponsor
Indian Council of Medical Research
Collaborators
Yakult Honsha Co., LTD
First posted
Sep 24, 2007
Start date
Jun 2007
Completion
Jan 2008 (estimated)
Last update
Sep 24, 2007

Study contacts

Dr.Dipika Sur, MD
principal investigator · National Institute of Cholera and Enteric Diseases, India

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion